Evidence map›Paper›PMID 41033711›Full record

ArticleOpen heart2025

Residual SYNTAX score and outcomes after TAVR+PCI versus SAVR+CABG: a propensity-matched, gender-based comparison.

Max Potratz, Vera Fortmeier, Katharina Höflsauer, Muhammed Gerçek, Isabel Horn, Georges El Hachem, Johannes Kirchner, Volker Rudolph, Smita Scholtz, Jan Gummert and 3 more

Abstract readComparative Study
In one paragraph

Article in Open heart, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Max PotratzClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany MPotratz@hdz-nrw.de.ORCID http://orcid.org/0000-0003-4044-7037
Vera FortmeierClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Katharina HöflsauerClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Muhammed GerçekClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Isabel HornClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Georges El HachemClinic for Thoracic and Cardiovascular Surgery, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Johannes KirchnerClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Volker RudolphClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.ORCID http://orcid.org/0000-0001-5385-6839
Smita ScholtzClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.ORCID http://orcid.org/0000-0002-7445-5986
Jan GummertClinic for Thoracic and Cardiovascular Surgery, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Charles J DavidsonCardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Sabine BleizifferClinic for Thoracic and Cardiovascular Surgery, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.
Tanja K RudolphClinic for General and Interventional Cardiology/Angiology, Herz und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAortic stenosis (AS) and coronary artery disease (CAD) frequently coexist, requiring careful revascularisation strategy consideration. While surgical aortic valve replacement (SAVR) plus coronary artery bypass grafting (CABG) is traditional, transcatheter aortic valve replacement (TAVR) plus percutaneous coronary intervention (PCI) is increasingly used. The optimal strategy, particularly regarding residual CAD burden, remains unclear.

objectivesThis study investigated the impact of residual SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score (rSS) on outcomes in men and women with AS and CAD undergoing TAVR+PCI versus SAVR+CABG.

methodsIn this retrospective study, propensity score-matched cohorts of men and women undergoing either procedure were analysed. Matching variables included age, left ventricular ejection fraction, EuroSCORE II (European System for Cardiac Operative Risk Evaluation II) and CAD severity.

results398 patients (114 women and 284 men) were included. The rSS was predictive of the primary composite endpoint in the TAVR+PCI group (p=0.006 women and p<0.001 men) but not in the SAVR+CABG group. In patients achieving an rSS<8, TAVR+PCI was associated with a lower combined endpoint rate compared with SAVR+CABG, consistent across genders (p=0.02). Furthermore, TAVR+PCI demonstrated significant safety benefits, including lower rates of major bleeding in men (2.1% vs 10.6%) and stroke in women (1.8% vs 12.3%).

conclusionsThe prognostic importance of the rSS is strategy-dependent. For patients undergoing TAVR+PCI, achieving extensive revascularisation (rSS <8) is a critical procedural goal associated with improved outcomes. For patients undergoing SAVR+CABG, prognosis appears driven more by baseline clinical risk.

Indexed as

Aortic ValveAortic Valve StenosisCoronary Artery BypassCoronary Artery DiseaseHeart Valve Prosthesis ImplantationPercutaneous Coronary InterventionPropensity ScoreTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleRetrospective StudiesRisk AssessmentAortic Valve StenosisCoronary Artery BypassHeart Valve ProsthesisHeart Valve Prosthesis ImplantationTranscatheter Aortic Valve Replacement

Identifiers

PMID41033711
PMCPMC12496072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.